Clinical TrialJun 10, 2026, 07:36 AM
Cullinan Therapeutics Reports Positive Clinical Data for CLN-978 & Velinotamig
AI Summary
Cullinan Therapeutics announced updated positive clinical data for CLN-978 in treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), demonstrating robust efficacy including clinical remission in RA and a favorable safety profile. Initial data for velinotamig in treatment-refractory SLE also showed promising clinical activity, with both treated patients achieving complete renal response and a favorable safety profile. The company plans further clinical development and data readouts for both programs in late 2026 and early 2027, including expansion into new indications.
Key Highlights
- CLN-978 Phase 1 RA trial showed DAS28-ESR remission in one poly-refractory patient, reducing score from 4.0 to 2.2 by week 4.
- CLN-978 Phase 1 SLE trial safety data for the first three multi-dose patients were consistent with a favorable safety profile.
- CLN-978 observations in SLE patients with nephritis showed rapid improvement in proteinuria, supporting Phase 2a expansion in early 2027.
- Velinotamig Phase 1b/2a trial in China showed both first two refractory SLE patients achieved complete renal response.
- Velinotamig reduced SLEDAI-2K scores from 16 and 14 at baseline to 0 and 2, respectively, at week 8 in two patients.
- Velinotamig demonstrated a favorable safety profile with no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.
- Additional multi-dose regimen data for CLN-978 in RA are expected in Q3 2026 and in SLE in Q4 2026.
- Cullinan plans to initiate a velinotamig Phase 1/2a clinical trial in autoimmune cytopenias in Q1 2027.
Price Impact
More from CGEM